Abstract | BACKGROUND: METHOD: Here we compare baseline cognitive, biomarker (structural imaging and cerebrospinal fluid) and other PD psychosis risk factor data in patients who go on to develop illusions or hallucinations within 3-4 years of follow-up in the Parkinson's Progression Markers Initiative cohort of newly diagnosed PD. RESULTS: Of n=423 patients with PD, n=115 (27%) reported predominantly illusions with the median time of onset at 19.5 months follow-up. At study entry these patients had reduced CSF amyloid Aß1-42, lower olfaction scores, higher depression scores and increased REM sleep behaviour disorder symptoms compared to patients without early onset PD psychosis but no differences in cognitive, higher visual or structural imaging measures. A subset of patients with early onset formed hallucinations (n=21) had reduced higher visual function at baseline, cortical thinning in parietal, occipital and frontal cortex and reduced hippocampal volume. CONCLUSIONS:
|
Authors | Dominic H Ffytche, Joana B Pereira, Clive Ballard, K Ray Chaudhuri, Daniel Weintraub, Dag Aarsland |
Journal | Journal of neurology, neurosurgery, and psychiatry
(J Neurol Neurosurg Psychiatry)
Vol. 88
Issue 4
Pg. 325-331
(Apr 2017)
ISSN: 1468-330X [Electronic] England |
PMID | 28315846
(Publication Type: Journal Article, Multicenter Study, Observational Study)
|
Copyright | Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. |
Chemical References |
- Amyloid beta-Peptides
- Peptide Fragments
- amyloid beta-protein (1-42)
|
Topics |
- Adult
- Aged
- Amyloid beta-Peptides
(cerebrospinal fluid)
- Cohort Studies
- Delusions
(diagnosis, epidemiology, psychology)
- Dementia
(diagnosis, epidemiology, psychology)
- Disease Progression
- Female
- Follow-Up Studies
- Hallucinations
(diagnosis, epidemiology, psychology)
- Humans
- Male
- Middle Aged
- Parkinson Disease
(diagnosis, epidemiology, psychology)
- Peptide Fragments
(cerebrospinal fluid)
- Psychotic Disorders
(diagnosis, epidemiology, psychology)
- Risk Factors
|